Advanced search
Publication Cover
Clinical Ophthalmology Volume 12, 2018 - Issue
Submit an article Journal homepage
298
Views
55
CrossRef citations to date
0
Altmetric
Review

Biosimilars in ophthalmology: “Is there a big change on the horizon?”

Ashish Sharma1 Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India, [email protected]Correspondence[email protected]
,
Prahalad Reddy1 Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India, [email protected]
,
Baruch D Kuppermann2 Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA
,
Francesco Bandello3 Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy
&
Anat Lowenstein4 Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Pages 2137-2143 | Published online: 24 Oct 2018

Citations (55)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (11)

Debdulal Chakraborty, Soumen Mondal, Subhendu Boral, Arnab Das, Tushar Kanti Sinha, Saptorshi Majumdar, Ranabir Bhattacharya & Ritobroto Maitra. (2023) Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence. Clinical Ophthalmology 17, pages 1067-1076.
Read now
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Anat Loewenstein, Francesco Bandello & Baruch D Kuppermann. (2023) Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia. Expert Opinion on Biological Therapy 23:8, pages 689-692.
Read now
Andrea Servillo, Ilaria Zucchiatti, Riccardo Sacconi, Mariacristina Parravano, Lea Querques, Paula La Rubia, Francesco Prascina, Francesco Bandello & Giuseppe Querques. (2023) The state-of-the-art pharmacotherapeutic management of neovascular age-related macular degeneration. Expert Opinion on Pharmacotherapy 24:2, pages 197-206.
Read now
Colin S Tan, Wei Kiong Ngo, Isaac W Chay, Dominic S Ting & SriniVas R Sadda. (2022) Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options. Clinical Ophthalmology 16, pages 917-933.
Read now
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Bandello & Baruch D Kuppermann. (2022) Emerging biosimilars for retinal diseases. Expert Review of Ophthalmology 17:6, pages 383-386.
Read now
Charalabos-Markos Dintsios. (2022) A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 283-297.
Read now
Stephanie Choi, Evan M. Chen, Dinah Chen, Jayanth Sridhar & Ravi Parikh. (2022) The Impact of International Pricing Index Models on Anti-Vascular Endothelial Growth Factor (VEGF) Drug Costs in the United States. Seminars in Ophthalmology 37:1, pages 23-28.
Read now
Masumi G. Asahi, Jaycob Avaylon, Josh Wallsh & Ron P. Gallemore. (2021) Emerging biological therapies for the treatment of age-related macular degeneration. Expert Opinion on Emerging Drugs 26:2, pages 193-207.
Read now
Danny S. C. Ng, Nicholas S. K. Fung, Fanny L. T. Yip & Timothy Y. Y. Lai. (2020) Ranibizumab for myopic choroidal neovascularization. Expert Opinion on Biological Therapy 20:12, pages 1385-1393.
Read now
Ee Lin Ong, Kimberly Spooner, Thomas Hong & Andrew Chang. (2020) Brolucizumab: an evolution in treatment for neovascular age-related macular degeneration. Expert Review of Ophthalmology 15:2, pages 71-81.
Read now
Amanda Haymond, Justin B. Davis & Virginia Espina. (2019) Proteomics for cancer drug design. Expert Review of Proteomics 16:8, pages 647-664.
Read now

Articles from other publishers (44)

Weiye Li & Jingfa Zhang. 2024. Therapeutic Targets for Diabetic Retinopathy. Therapeutic Targets for Diabetic Retinopathy 215 263 .
Ruchi Agarwal, Sanjiv K Gupta & Siddharth Agrawal. (2023) Efficacy and safety analysis of intravitreal bio-similar products of bevacizumab in patients with macular edema because of retinal diseases. Indian Journal of Ophthalmology 71:5, pages 2066-2070.
Crossref
Casey Zhang, Scott Friedman, Prithvi Mruthyunjaya & Ravi Parikh. (2023) The Biosimilar Paradox: How Anti-VEGF Biosimilars will Increase Patient and Overall Healthcare Costs. Ophthalmology.
Crossref
Neil M Bressler, Miroslav Veith, Jan Hamouz, Jan Ernest, Dominik Zalewski, Jan Studnička, Attila Vajas, András Papp, Gabor Vogt, James Luu, Veronika Matuskova, Young Hee Yoon, Tamás Pregun, Taehyung Kim, Donghoon Shin, Inkyung Oh, Hansol Jeong, Mercy Yeeun Kim & Se Joon Woo. (2023) Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. British Journal of Ophthalmology 107:3, pages 384-391.
Crossref
Eric E. Jung, Thomas C. Lee & Aaron Nagiel. (2023) Initial Experience With Biosimilar Bevacizumab-bvzr For Intravitreal Use in Children: A Case Series and Literature Review. Ophthalmic Surgery, Lasers and Imaging Retina 54:2, pages 84-88.
Crossref
Monika Kapur, Suvansh Nirula & Mayuresh P. Naik. (2022) Future of anti-VEGF: biosimilars and biobetters. International Journal of Retina and Vitreous 8:1.
Crossref
Chang Ki Yoon, Jaeryung Oh, Kunho Bae, Un Chul Park, Kyung-Sang Yu & Hyeong Gon Yu. (2022) Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial. PLOS ONE 17:11, pages e0275611.
Crossref
Ashish Sharma, Lihteh Wu, Steven Bloom, Paulo Stanga, Barbara Parolini, Veronika Matello & Kourous A. Rezaei. (2022) RWC Update: Biosimilar Biologics—Need for Real World Data; Autologous Choroidal Transplantation for Wet AMD. Ophthalmic Surgery, Lasers and Imaging Retina 53:11, pages 602-605.
Crossref
Jingfa Zhang, Jingxiang Zhang, Chaoyang Zhang, Jingting Zhang, Limin Gu, Dawei Luo & Qinghua Qiu. (2022) Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells 11:21, pages 3362.
Crossref
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Carl Regillo, Francesco Bandello & Baruch D. Kuppermann. (2022) Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?. Eye.
Crossref
Aira Sarkar, Srushti Jayesh Sodha, Vijayabhaskarreddy Junnuthula, Praveen Kolimi & Sathish Dyawanapelly. (2022) Novel and investigational therapies for wet and dry age-related macular degeneration. Drug Discovery Today 27:8, pages 2322-2332.
Crossref
Angeliki Velentza-Almpani, Nkiruka Ibeanu, Tianyang Liu, Christopher Redhead, Peng Tee Khaw, Steve Brocchini, Sahar Awwad & Yann Bouremel. (2022) Effects of Flow Hydrodynamics and Eye Movements on Intraocular Drug Clearance. Pharmaceutics 14:6, pages 1267.
Crossref
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Carl D. Regillo, Francesco Bandello & Baruch D. Kuppermann. (2022) Retina: a unique subspecialty in the biosimilar landscape. Eye 36:6, pages 1145-1146.
Crossref
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Bandello, Baruch D. Kuppermann & Anat Loewenstein. (2021) Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). Eye 36:5, pages 1106-1107.
Crossref
Debdulal Chakraborty, Sabyasachi Sengupta, Soumen Mondal, Subhendu Boral, Arnab Das, Tushar Kanti Sinha, Ranabir Bhattacharya & Ritobroto Maitra. (2022) Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study. Ophthalmology and Therapy 11:2, pages 629-638.
Crossref
Ana Rita Fernandes, Aleksandra Zielińska, Elena Sanchez-Lopez, Tiago dos Santos, Maria Luisa Garcia, Amelia M. Silva, Jacek Karczewski & Eliana B. Souto. (2022) Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options. International Journal of Molecular Sciences 23:5, pages 2592.
Crossref
Dhanashree Ratra, Krishnakanta Roy, Sneha Giridhar, Sushant Madaan, Pramod Bhende, Muna Bhende, Girish Rao, Parveen Sen, Rajiv Raman, Vikas Khetan, Chetan Rao, S. Pradeep, Vinata Muralidharan, G. Suganeswari, Rupak Roy, Debmalya Das, Suchetana Mukherjee, P. S. Rajesh, V. Jayaprakash, Eesh Nigam, C. Charanya, S. Sruthi, Maitreyi Chowdhury & Kalpita Das. (2021) Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation. Ophthalmology and Therapy 11:1, pages 135-149.
Crossref
Ashish Sharma, Baruch D Kuppermann & Anat Loewenstein. (2022) The Future of Biosimilars and Biobetters in Ophthalmology. US Ophthalmic Review 16:1, pages 6.
Crossref
Sho Fujiwara, Tsutomu Ueda, Naoki Ishii, Yoshihiko Abe, Kayoko Hayashihara-Kakuhou, Kimitoshi Takeda, Takaaki Kurinomaru, Ayano Fukuhara, Susumu Uchiyama & John F. Carpenter. (2022) Chemical-gas Sterilization of External Surface of Polymer-based Prefilled Syringes and Its Effect on Stability of Model Therapeutic Protein. Journal of Pharmaceutical Sciences 111:1, pages 41-50.
Crossref
Dionysis D. Balatsoukas, Konstantinos T. Tsaousis, Konstadinos G. Boboridis, Anastasios G. Konstas & Fotis Topouzis. (2021) Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview. Advances in Therapy 39:1, pages 5-32.
Crossref
Mariacristina Parravano, Eliana Costanzo, Giulia Scondotto, Gianluca Trifirò & Gianni Virgili. (2021) Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. BioDrugs 35:6, pages 673-692.
Crossref
Sruthi Arepalli & Peter K. Kaiser. (2021) Pipeline therapies for neovascular age related macular degeneration. International Journal of Retina and Vitreous 7:1.
Crossref
Nhon T. Le, Zachary A. Kroeger, Weijie Violet Lin, Arshad M. Khanani & Christina Y. Weng. (2021) Novel Treatments for Diabetic Macular Edema and Proliferative Diabetic Retinopathy. Current Diabetes Reports 21:10.
Crossref
Shashikant Sharma, Tanishq Sharma, Somdutt Prasad, Mahesh Gopalakrishnan & Alok Chaturvedi. (2021) Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review. Ophthalmology and Therapy 10:3, pages 431-443.
Crossref
Preethi B, Shilpa G, Dhwani Anil Shah & Praveen R Murthy. (2021) A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM. Indian Journal of Clinical and Experimental Ophthalmology 7:2, pages 346-351.
Crossref
Debdulal Chakraborty, Michael W. Stewart, Jay U. Sheth, Tushar K. Sinha, Subhendu Boral, Arnab Das, Soumen Mondal & Angshuman Mukherjee. (2021) Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases. Ophthalmology and Therapy 10:2, pages 337-348.
Crossref
Raja Narayanan, Seenu M. Hariprasad & Jay Sheth. (2021) Biosimilars for the Treatment of Retinal Diseases. Ophthalmic Surgery, Lasers and Imaging Retina 52:5, pages 242-246.
Crossref
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Bandello, Baruch D. Kuppermann & Anat Loewenstein. (2021) Biosimilars for Retinal Diseases: An Update. American Journal of Ophthalmology 224, pages 36-42.
Crossref
María L. Formica, Hamoudi G. Awde Alfonso & Santiago D. Palma. (2021) Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology. Pharmacology Research & Perspectives 9:2.
Crossref
AdityaS Kelkar, Jai Kelkar, Mounika Bolisetty & ShreekantB Kelkar. (2021) Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence. Indian Journal of Ophthalmology 69:6, pages 1469.
Crossref
JayU Sheth, MichaelW Stewart, Manoj Khatri, ShashankR Gupta, Shobhit Chawla, Anand Rajendran & Raja Narayanan. (2021) Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey. Indian Journal of Ophthalmology 69:2, pages 352.
Crossref
Matthew Collins, Sahar Awwad, Nkiru Ibeanu, Peng T. Khaw, David Guiliano, Steve Brocchini & Hanieh Khalili. (2021) Dual-acting therapeutic proteins for intraocular use. Drug Discovery Today 26:1, pages 44-55.
Crossref
Gitanjali Sharma, Chen Zhou, Saurabh Wadhwa, Ashwin C. Parenky, Kenneth S. Graham, Amardeep S. Bhalla, Dingjiang Liu, Hunter H. Chen & Mohammed Shameem. 2021. Ophthalmic Product Development. Ophthalmic Product Development 463 509 .
Ahmad M. Mansour, Michael W. Stewart, Michel E. Farah, Hana A. Mansour & Jay Chhablani. (2019) Ziv‐aflibercept: A cost‐effective, off‐label, highly potent antagonist of vascular endothelial growth factor. Acta Ophthalmologica 98:5.
Crossref
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Rohini Sharma, Francesco Bandello, Baruch D. Kuppermann & Anat Loewenstein. (2020) Brolucizumab-key learnings from HAWK and HARRIER. Eye 34:8, pages 1318-1320.
Crossref
Alireza Lashay, Hamid Riazi-Esfahani, Hooshang Faghihi, Ahmad Mirshahi, Hassan Khojasteh, Alireza Khodabande, Fahimeh Asadi Amoli, Fariba Ghassemi, Fatemeh Bazvand, Elias Khalili Pour, Nazanin Ebrahimiadib, Ali Torkashvand & Elham Delrish. (2020) Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes. Journal of Ophthalmology 2020, pages 1-6.
Crossref
Ashish Sharma, M. Hafeez Faridi, Nilesh Kumar, Nikulaa Parachuri, Rohini Sharma, Baruch D. Kuppermann, Francesco Bandello, Anat Loewenstein & Carl D. Regillo. (2019) Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye 34:6, pages 1008-1009.
Crossref
Ashish Sharma, Nilesh Kumar, Francesco Bandello, Anat Loewenstein & Baruch D. Kuppermann. (2019) Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye 34:6, pages 1006-1007.
Crossref
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Baruch D Kuppermann, Francesco Bandello & Carl D. Regillo. (2019) Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression. Eye 34:3, pages 422-423.
Crossref
Dheepak Sundar, Taraprasad Das, Jay Chhablani, Atul Kumar & Namrata Sharma. (2020) All India Ophthalmological Society members' survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection. Indian Journal of Ophthalmology 68:6, pages 1095.
Crossref
Ashish Sharma, Nilesh Kumar, Baruch D Kuppermann, Francesco Bandello & Anat Loewenstein. (2020) Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. British Journal of Ophthalmology 104:1, pages 2-7.
Crossref
Eduardo Tomazoni & Eduardo Buchelle Rodrigues. 2020. Choroidal Neovascularization. Choroidal Neovascularization 331 341 .
Seung Kook Baek, Jae Hui Kim, Jong Woo Kim & Chul Gu Kim. (2019) Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment. Scientific Reports 9:1.
Crossref
Ashish Sharma, Nilesh Kumar, Baruch D. Kuppermann, Francesco Bandello & Anat Loewenstein. (2019) Biologics, biosilimars, and biobetters: different terms or different drugs?. Eye 33:7, pages 1032-1034.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.